This article is more than 5 years old. Information may no longer be current.

Hi-Tech Pharmacal receives approval for dorzolamide, timolol ophthalmic solution

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

AMITYVILLE, N.Y. — The U.S. Food and Drug Administration has approved Hi-Tech Pharmacal's abbreviated new drug application for dorzolamide hydrochloride and timolol maleate ophthalmic solution, the company announced in a press release.

Hi-Tech's dorzolamide and timolol solution is the generic equivalent of Merck's Cosopt ophthalmic solution and is indicated for reducing elevated IOP in patients with ocular hypertension or open-angle glaucoma.

Hi-Tech plans to launch the solution immediately.